Background: This study aims to compare allele and genotype frequencies of a 30-bp variable number of tandem repeats (VNTR) polymorphism of the DAT1 gene, located at intron 8, between adult crack cocaine users and nonaddicted individuals. Due to its involvement in drug addiction, this gene is a good candidate for molecular studies. Methods: A cross-sectional sample of 239 current adult crack abusers or dependents from in- and outpatient clinics and 211 control individuals was collected in Brazil. They were evaluated using ASRS, ASI-6, WAIS-III, and MINI assessments. DNA samples extracted from whole blood were genotyped for the intron 8 VNTR in DAT1. Results: Logistic regression analysis was performed and controlled for gender, age, ethnicity, educational level, and comorbidities of clinical interest (generalized anxiety disorder, suicide risk, major depressive episode, and attention deficit/hyperactivity disorder). This analysis showed that the 6R6R genotype was associated with crack cocaine addiction (OR = 1.844; CI = 1.101–3.089; p = 0.020). Conclusions: Our results are consistent with the role of DAT1 in the neurobiology of drug addiction. Nevertheless, the study of other genes, environmental factors, and their interactions is also important to gain a broader understanding of this condition.

1.
Volkow ND, Wang GJ, Fowler JS, Tomasi D: Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol 2012; 52: 321–336.
2.
Lohoff FW, Bloch PJ, Hodge R, Nall AH, Ferraro TN, Kampman KM, Dackis CA, O’Brien CP, Pettinati HM, Oslin DW: Association analysis between polymorphisms in the dopamine D2 receptor (DRD2) and dopamine transporter (DAT1) genes with cocaine dependence. Neurosci Lett 2010; 473: 87–91.
3.
Laranjeira RCSM, Pinsky I, Caetano R, Sendin Mitsuhiro S: II LENAD – Levantamento Nacional de Álcool e Drogas. São Paulo, INPAD, 2012.
4.
Center for Behavioral Health Statistics and Quality: 2015 National Survey on Drug Use and Health: methodological summary and definitions. Rockville, Substance Abuse and Mental Health Services Administration, 2016.
5.
Blum K, Chen AL, Giordano J, Borsten J, Chen TJ, Hauser M, Simpatico T, Femino J, Braverman ER, Barh D: The addictive brain: all roads lead to dopamine. J Psychoactive Drugs 2012; 44: 134–143.
6.
Kendler KS, Karkowski LM, Neale MC, Prescott CA: Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch Gen Psychiatry 2000; 57: 261–269.
7.
Kendler KS, Myers J, Prescott CA: Specificity of genetic and environmental risk factors for symptoms of cannabis, cocaine, alcohol, caffeine, and nicotine dependence. Arch Gen Psychiatry 2007; 64: 1313–1320.
8.
Gelernter J, Kranzler HR, Satel SL, Rao PA: Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology 1994; 11: 195–200.
9.
Brousse G, Vorspan F, Ksouda K, Bloch V, Peoc’h K, Laplanche JL, Mouly S, Schmidt J, Llorca PM, Lepine JP: Could the inter-individual variability in cocaine-induced psychotic effects influence the development of cocaine addiction? Towards a new pharmacogenetic approach to addictions. Med Hypotheses 2010; 75: 600–604.
10.
Fernàndez-Castillo N, Ribasés M, Roncero C, Casas M, Gonzalvo B, Cormand B: Association study between the DAT1, DBH and DRD2 genes and cocaine dependence in a Spanish sample. Psychiatr Genet 2010; 20: 317–320.
11.
Ballon N, Leroy S, Roy C, Bourdel MC, Olie JP, Charles-Nicolas A, Krebs MO, Poirier MF: Polymorphisms TaqI A of the DRD2, BalI of the DRD3, exon III repeat of the DRD4, and 3′ UTR VNTR of the DAT: association with childhood ADHD in male African-Caribbean cocaine dependents? Am J Med Genet B Neuropsychiatr Genet 2007; 144B:1034–1041.
12.
Stolf AR, Szobot CM, Halpern R, Akutagava-Martins GC, Müller D, Guimaraes LS, Kessler FH, Pechansky F, Roman T: Crack cocaine users show differences in genotype frequencies of the 3′ UTR variable number of tandem repeats of the dopamine transporter gene (DAT1/SLC6A3). Neuropsychobiology 2014; 70: 44–51.
13.
Guindalini C, Howard M, Haddley K, Laranjeira R, Collier D, Ammar N, Craig I, O’Gara C, Bubb VJ, Greenwood T, Kelsoe J, Asherson P, Murray RM, Castelo A, Quinn JP, Vallada H, Breen G: A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc Natl Acad Sci USA 2006; 103: 4552–4557.
14.
Isaza C, Henao J, Beltrán L, Porras L, Gonzalez M, Cruz R, Carracedo A: Genetic variants associated with addictive behavior in Colombian addicted and non-addicted to heroin or cocaine. Colombia Médica 2013; 44: 19–25.
15.
Lahiri D, Nurnberger JJ: A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991; 19: 5444.
16.
Sano A, Kondoh K, Kakimoto Y, Kondo I: A 40-nucleotide repeat polymorphism in the human dopamine transporter gene. Hum Genet 1993; 91: 405–406.
17.
Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE: Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007; 39: 17–23.
18.
Buxbaum JD, Baron-Cohen S, Devlin B: Genetics in psychiatry: common variant association studies. Mol Autism 2010; 1: 6.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.